lapatinib has been researched along with Mesothelioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Civiello, G; Janne, PA; Johnson, BE; Mukohara, T | 1 |
2 other study(ies) available for lapatinib and Mesothelioma
| Article | Year |
|---|---|
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Topics: Antibiotics, Antineoplastic; Butadienes; Cell Cycle; Chromones; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mesothelioma; Mitogen-Activated Protein Kinase 3; Morpholines; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pleural Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Sirolimus; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |